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Purinergic receptors are divided into P1 (adenosine) and P2 
(ATP, ADP) receptors,1 with P2 subdivided into P2X (trimeric ion 
channels) and P2Y (metabotropic G-coupled receptors).2 The eight 
members of the P2Y family of receptors, so far characterized, have 
been further subdivided based on their primary signaling through 
specific coupled G-proteins. The first subgroup P2Y1,2,4,6,11 act 
through Gq and the second group, P2Y12,13,14, through Gi.
3 The 
P2Y2 receptor (P2Y2R) has been found in a variety of different 
tissues and cell types. Cell types include: epithelial cells, 
endothelial cells, smooth muscles cells and leukocytes. A study 
using P2Y2 knockout mice revealed that the receptor mediates 85-
95% of nucleotide-stimulated chloride secretion in the trachea. 
This suggests that P2Y2R agonists have therapeutic potential as a 
treatment for cystic fibrosis (CF), as activation of this chloride 
secretion channel could compensate for the defective chloride 
secretion in the respiratory epithelium of CF patients.4, 5 Indeed, a 
P2Y2 agonist, diquafosol 2, mediating chloride secretion, has been 
approved in Japan for the topical treatment of dry eye disease.6 
Agonism of the P2Y2R can also lead to keratinocyte 
proliferation and neutrophil migration, indicating that P2Y2 
antagonists have therapeutic potential as a treatment for psoriasis.5, 
7 It has also been reported that ATP released from tumor-cell 
activated platelets, acting through the P2Y2R, induce opening of 
the endothelial barrier, leading to migration of tumor cells and 
hence cancer proliferation. P2Y2R antagonists, therefore have 
therapeutic potential as anti-metastatic agents.8  
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Despite the appeal of the P2Y2R as an important drug target, 
limited reports on P2Y2R antagonists have appeared to date
9–11 and 
indeed the only reported discovery of drug-like P2Y2R 
antagonists12 is from an industrial research group within 
AstraZeneca, disclosed within a series of chemical patents.13,14 
One of the most potent and selective of these antagonists, AR-
C118925, has been used as a tool for pharmacological studies on 
the P2Y2 receptor.
15,16  More recently, its selectivity profile against 
a range of P2 receptors has been published. AR-C118925 was at 
least 50-fold selective against P2Y4, P2Y6, P2Y11, P2Y12, P2Y14, 
P2X2, P2X4 and P2X7, whilst ~ 40-fold against P2X1 and ~15-fold 
against P2X3. 
17 
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The G protein-coupled P2Y2 receptor, activated by ATP and UTP has been reported as a potential 
drug target for a wide range of important clinical conditions, such as tumor metastasis, kidney 
disorders, and in the treatment of inflammatory conditions. However, pharmacological studies on 
this receptor have been impeded by the limited reported availability of stable, potent and selective 
P2Y2R antagonists. This article describes the design and synthesis of AR-C118925, a potent and 
selective non-nucleotide antagonist of the P2Y2 receptor discovered using the endogenous P2Y2R 
agonist UTP as the chemical starting point.     
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Herein we report the design and synthesis of P2Y2R 
antagonists, which led to the discovery of AR-C118925. 
In the absence of a high throughput screening (HTS), the 
endogenous agonists, adenosine triphosphate (ATP) 3 and uridine 
triphosphate (UTP) 4 were considered as starting points for the 
research program. The greater selectivity of UTP for P2Y2R over 
the other P2 purinoceptors led to its selection as the chemical 
starting point.  Replacing the βγ-oxygen of the triphosphate moiety 
of UTP with a dichloromethylene unit and substitution of the 
oxygen in the 4-position of the uracil with sulfur, gave enhanced 
metabolic stability, whilst maintaining agonist activity.18–20 
Interestingly, it was discovered that that P2Y2R antagonism could 
be achieved through substitution of the 5-position of the uracil ring 
with lipophilic substituents (Table 1). The introduction of a 
benzhydryl group into this position (5) gave a compound with a 
pA2 for the P2Y2R of 6. P2Y2R activity was substantially increased 
by either symmetrically adding substituents to the benzhydryl 
group, compounds 6, 7, 8, and 9,  or by linking the two phenyl 
rings of the benzhydryl to form a tricycle, compounds 10, 11, 12, 
and 13, with the highest activity achieved with the 
dibenzosuberenyl group, compound 13 (pA2 8.5).  
Table 1: Exploration of the 5-position of the uracil ring 
 
 
Compound P2Y2 pA2a, b 
5 6.0 ± 0.2 
6 7.9 ± 0.2 
7 7.8 ± 0.2 
8 7.1 ± 0.2 
9 7.7 ± 0.2 
10 7.2 ± 0.2 
11 7.3 ± 0.2 
12 8.0 ± 0.2 
13 8.5 ± 0.2 
a) The assay used a human P2Y2R clone which was isolated 
from HL60 cells cDNA and then stably transfected into a Jurkat 
cell line. The cloned receptor mediates an increase in intracellular 
calcium in the cell line, which possesses no endogenous nucleotide 
receptor of its own. Inhibition of UTP mediated calcium responses 
were measured using 17 ktM fluo-3AM dye on a SPEX Fluomax 
using 508 nm excitation and 525 nm emission wavelengths at 
room temperature.b n=≥2 replicates 
The P2Y2R antagonist program ultimately required the 
development of an oral drug-like compound.21 This necessarily 
meant moving away from the high molecular weight, highly 
charged substituted nucleotides. Removing the triphosphate group 
gave the nucleoside analogue 14 (Table 2). Whilst this compound 
was substantially less potent than its parent triphosphate 13, it did 
retain some antagonist activity (pA2 4.7). Furthermore, it was 
discovered that the ribose ring could be replaced with the 
structurally less complex 3-methylenebenzoic acid to give 15, with 
a slight gain in activity. The rationale for having the carboxylic 
acid was to mimic any binding interactions the alpha phosphate of 
UTP might have with the P2Y2R. 
Table 2: Replacement of the ribose-triphosphate group 
 
 
Compound X P2Y2 pA2a 
14 S 4.7 ± 0.2 
15 S 5.4 ± 0.2 
16 S 5.7 ± 0.2 
17 S 5.6 ± 0.2 
18 S 5.4 ± 0.2 
19 S 5.9 ± 0.2 
20 S 5.7 ± 0.2 
21 O 4.4 ± 0.2 
22 S 5.8 ± 0.2 
23 S 5.2 ± 0.2 
24 S 5.6 ± 0.2 
a n=≥2 replicates 
Changing the linker between the carboxylic acid and phenyl 
ring from a direct bond to a one or two atom linker, potentially 
placing the carboxylic acid group further into the triphosphate 
binding region, gave a small increase in activity (16 and 17). In 
addition, the P2Y2R appeared tolerant of a range of hetero 
aromatic replacements for the phenyl ring. For example, the 
furanyl analogue 19 had a further slight gain in activity (pA2 5.9). 
The continuing importance of the 4-thiouracil relative to uracil was 
demonstrated with thiazole replacement, where the uracil analogue 
was > 10-fold less potent (compare compound 20 with 21). 
Having been able to replace the ribose triphosphate with a 
structurally less complicated and synthetically less challenging 
group, P2Y2R antagonism could be increased through symmetrical 
substitution on the 5-suberenyl substituent 25, 26 and 27 (Table 
3). This combines the two features of change to the 5-benzhydryl 
group in the ribose triphosphate series, which independently gave 
an increase in receptor antagonism (Table 1).  
 
Table 3: Further changes to the substituent on the 1-position 
of the uracil ring 
 
 
Compound R’ P2Y2 pA2a 
25 Me 7.0 ± 0.2 
26 Cl 6.7 ± 0.2 
27 Me 6.6 ± 0.2 
28 Me 7.4 ± 0.2 
29 Me 7.6 ± 0.2 
30 Me 7.5 ± 0.2 
31 Me 7.2 ± 0.2 
1 Me 7.8 ± 0.2 
a n=≥2 replicates 
In a similar manner to compounds discussed in Table 2, moving 
the acidic group further into the triphosphate binding region gave 
an increase in receptor antagonism. Although the dicarboxylic 
acids 28 and 29 had similar activity to the mono carboxylic acid 
30, indicating perhaps that only one of the carboxylic acids is 
involved in binding to the receptor. Finally, bioisosteric 
replacement of the carboxylic acid was employed giving the most 
potent compound, AR-C118925 (1). 
 
Scheme 1: Representative synthesis of nucleotide analogues (5-13). (a) (i) 
TMEDA (2.2 eq), secBuLi (2.1 eq), THF, -78oC (ii) 5-dibenzosuberenone 
(1.5 eq), THF, 55% (b) (i) Et3SiH (2 eq), BF3.Et2O (2 eq), CH2Cl2, 0
oC (ii) 
tBuMe2SiCl (1.5 eq), imidazole (1.5 eq), DMF,  70% (c) P4S10, pyridine, 
reflux, 68% (d) TBAF, THF, r.t., 85% (e) (i) 1.3 eq POCl3, (1.3 eq) proton 
sponge, PO(OEt)3 (ii) clodronic acid (3 eq), 
nBu3N (9 eq), PO(OEt)3, 16%. 
 
Scheme 1, which shows the synthesis of compound 13, 
illustrates the general procedure for synthesising the compounds 
in Table 1. Selective lithiation of the 5-position of the uracil ring 
(32) using the method of Miyasaka22 followed by addition of 5-
dibenzosuberenone gave the 5-dibenzosuberenol (33). The alcohol 
was then reduced using triethylsilane and borontrifluoride 
etherate. During this reaction, there was some loss of the silyl 
protecting groups, giving a mixture of mono, di and tri silylated 
products. Reprotection using standard procedure gave the 
trisilylated product (33). Thiation of the 4-position of the uracil 
was achieved using P4S10 in pyridine under reflux and removal of 
the silyl protecting groups using tetrabutylammonium fluoride 
gave the 5-substituted 4-thiouridine (14). Phosphorylation of the 
5’-position of the ribose was achieved using phosphorus 
oxychloride followed by treatment with clodronic acid. The crude 
product was purified using DEAE Sephadex® ion exchange 
chromatography eluting with a 0 to 1 molar gradient of 
triethylammonium bicarbonate followed by elution through a Na+ 
form Dowex® ion exchange column to give the sodium salt of the 
product (13). 
 
Scheme 2: Synthesis of AR-C118925. (a) (i) nBuLi, THF. -78oC (ii) 2,8-
dimethyldibenzosuberanone, THF (b) AcOH, reflux, 96% over two steps  (c) 
(i) BSTFA (2.2 eq), 1,2-dichloroethane, reflux (ii) 5-bromomethyl-2-
furancarboxylic acid methyl ester, MeCN, reflux, 53% (d) Lawesson's reagent 
(1 eq.), 1,4-dioxane reflux, 65% (e) LiOH (5 eq.), 3:1 MeOH:H2O, r.t., 95% 
(f) aminotetrazole, (1.5 eq) pybrop (1.5 eq), NEt3 (3 eq), DMF, 60%. 
 
The synthesis of AR-C118925 is shown in scheme 2. Bromo 
lithium exchange of 5-bromo-2,4-di-tert-butoxypyrimidine23 
followed by treatment with 2,8-dimethyldibenzosuberanone gave 
the corresponding dibenzosuberanol product (34). Treatment with 
acetic acid under reflux gave the 5-substituted uracil (35) in very 
good yield over the two steps. Bis-silylation of uracil (35) followed 
by treatment with 5-bromomethyl-2-furancarboxylic acid methyl 
ester, selectively alkylated in the 1-position of the uracil. 
Treatment with Lawesson’s reagent then effected the conversion 
to the 4-thio uracil. Hydrolysis of the methyl ester gave the 
carboxylic acid (25) in good yield. Activation of the carboxylic 
acid with bromo-tris(pyrrolidino)phosphonium 
hexafluorophosphate and coupling with 1-aminotetrazole gave 
AR-C118925 (1). 
In conclusion, a potent and selective non nucleotide P2Y2R 
antagonist, AR-C118925, was discovered using the endogenous 
agonist UTP as the chemical starting point for the program. AR-
C118925 has reasonable physicochemical properties for a tool 
compound (MWt 537, LogD7.4 of 2.26) and was shown to have a 
reasonable rat in vivo pharmacokinetics [i.v. clearance (75 
mL/min/Kg), Vss 4.34 L/Kg, T1/2 2.12 h)] but was not bioavailable 
(F 0%). This approach of starting with the endogenous ligand has 
also been used in the P2Y12  program 
24 and complimented the 
alternative, HTS – Active to Hit, Hit to Lead approach to initiating 
receptor agonist/antagonist projects at AstraZeneca.25–27 
Utilization of AR-C118925 in the chemical literature supporting 
future potential clinical applications for P2Y2R antagonists has 
necessitated this present disclosure and we will be reporting 
further studies in due course.  
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